Skip to main content

HESA Committee Report

If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.

Bill C-368, An Act to amend the Food and Drugs Act (natural health products)
In accordance with its Order of Reference of Wednesday, May 29, 2024, your committee has considered Bill C-368, An Act to amend the Food and Drugs Act (natural health products), and agreed on Thursday, November 28, 2024, to report it with the following amendments:

Clause 1

That Bill C-368, in Clause 1, be amended by replacing lines 7 to 11 on page 1 with the following:

therapeutic product means

(a) a drug or device;

(b) any combination of drugs and devices; or

(c) a natural health product, within the meaning of the Natural Health Products Regulations, that contains nicotine, or its salts, and is used in nicotine replacement therapy; (produit thérapeutique)”

New Clause 1.1

That Bill C-368 be amended by adding after line 11 on page 1 the following new clause:

“1.1 The Act is amended by adding the following after section 2.2:

2.21 Despite the definition therapeutic product in section 2, sections 21.3 to 21.303 and the regulations made under paragraphs 30(1.2)(f.01) and (f.02) apply to a natural health product within the meaning of the Natural Health Products Regulations.”

New Clause 3.1

That Bill C-368 be amended by adding after line 13 on page 1 the following new clause:

“3.1 Subsection 30(1.2) of the Act is amended by adding the following after paragraph (f):

(f.01) respecting the recall of natural health products within the meaning of the Natural Health Products Regulations;

(f.02) prescribing penalties for the contravention of subsection 21.3(3) in respect of a natural health product within the meaning of the Natural Health Products Regulations or of the regulations made under paragraph (f.01);”

Your committee has ordered a reprint of Bill C-368, as amended, as a working copy for the use of the House of Commons at the report stage.
A copy of the relevant Minutes of Proceedings (Meetings Nos. 132, 135, 136, 138 to 140 and 142) is tabled.